12 February 2024 - Approval is based on the Phase 3 KEYNOTE-811 Trial.
Merck announced that Health Canada has granted approval of Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2 positive gastric or gastro-oesophageal junction adenocarcinoma whose tumours express PD-L1 (combined positive score ≥ 1) as determined by a validated test.